ABT

127.04

0.58% -0.74

Pre-mercato: 126.92 -0.12 -0.09%

Abbott Laboratories (ABT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$127.78

Aprire:

$128.45

Volume 24 ore:

6.62M

Relative Volume:

1.08

Capitalizzazione di mercato:

$220.91B

Reddito:

$43.84B

Utile/perdita netta:

$13.90B

Rapporto P/E:

15.93

EPS:

7.9725

Flusso di cassa netto:

$6.92B

1 W Prestazione:

+1.40%

1M Prestazione:

+1.57%

6M Prestazione:

-4.98%

1 anno Prestazione:

+12.03%

Intervallo 1D:

$126.27

$128.60

Intervallo di 1 settimana:

$122.50

$129.46

Portata 52W:

$110.86

$140.84

Abbott Laboratories Stock (ABT) Company Profile

Nome

Abbott Laboratories

Settore

Healthcare (1115)

Industria

Medical Devices (142)

Telefono

(224) 667-6100

Indirizzo

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Dipendente

114,000

Cinguettio

@AbbottNews

Prossima data di guadagno

2025-10-15

Ultimi documenti SEC

ABT's Discussions on Twitter

Confronta ABT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ABT Abbott Laboratories	127.04	222.19B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	98.65	144.97B	19.35B	2.78B	3.82B	1.8696
SYK Stryker Corp	367.75	140.12B	24.38B	2.94B	4.07B	7.6159
MDT Medtronic Plc	99.77	128.60B	34.76B	4.79B	5.21B	3.7017
EW Edwards Lifesciences Corp	84.83	49.82B	5.88B	1.34B	799.60M	2.3489

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-10	Iniziato	The Benchmark Company	Buy
2025-07-18	Aggiornamento	Jefferies	Hold → Buy
2025-06-16	Iniziato	Leerink Partners	Market Perform
2024-10-08	Iniziato	Oppenheimer	Outperform
2024-09-19	Iniziato	Piper Sandler	Overweight
2024-07-30	Downgrade	Edward Jones	Buy → Hold
2024-05-30	Iniziato	Goldman	Buy
2023-07-21	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2023-05-30	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-04-20	Reiterato	Barclays	Overweight
2023-04-20	Reiterato	Bernstein	Outperform
2023-04-20	Reiterato	JP Morgan	Overweight
2023-04-20	Reiterato	Raymond James	Outperform
2023-04-20	Reiterato	UBS	Buy
2023-04-20	Reiterato	Wolfe Research	Underperform
2023-03-29	Iniziato	UBS	Buy
2022-10-26	Iniziato	Mizuho	Neutral
2022-10-18	Iniziato	Barclays	Overweight
2022-10-12	Iniziato	Jefferies	Hold
2022-07-06	Iniziato	Wolfe Research	Underperform
2022-03-02	Ripresa	BofA Securities	Buy
2022-01-27	Reiterato	Credit Suisse	Outperform
2022-01-27	Reiterato	Morgan Stanley	Overweight
2022-01-27	Reiterato	Raymond James	Outperform
2022-01-27	Reiterato	UBS	Buy
2021-12-10	Iniziato	RBC Capital Mkts	Outperform
2021-10-27	Aggiornamento	Atlantic Equities	Neutral → Overweight
2021-10-14	Iniziato	Redburn	Neutral
2021-05-25	Iniziato	Barclays	Overweight
2021-04-15	Iniziato	Atlantic Equities	Neutral
2021-01-28	Aggiornamento	BTIG Research	Neutral → Buy
2020-09-11	Iniziato	Wolfe Research	Outperform
2020-06-01	Downgrade	Goldman	Neutral → Sell
2020-03-05	Iniziato	Citigroup	Buy
2020-02-13	Iniziato	Goldman	Neutral
2020-02-06	Ripresa	BTIG Research	Neutral
2020-01-02	Downgrade	Guggenheim	Buy → Neutral
2019-06-13	Reiterato	BofA/Merrill	Buy
2019-02-07	Reiterato	BofA/Merrill	Buy
2019-01-02	Downgrade	Citigroup	Neutral → Sell
2018-11-30	Aggiornamento	Goldman	Neutral → Buy
2018-10-16	Iniziato	Barclays	Overweight
2018-06-27	Iniziato	Bernstein	Outperform
2018-01-30	Reiterato	Citigroup	Neutral
2018-01-25	Reiterato	Stifel	Buy
2018-01-25	Aggiornamento	William Blair	Mkt Perform → Outperform
2018-01-03	Iniziato	Evercore ISI	Outperform
2018-01-02	Aggiornamento	JP Morgan	Neutral → Overweight
2018-01-02	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2017-10-19	Reiterato	RBC Capital Mkts	Outperform
2017-10-19	Reiterato	Stifel	Buy

Mostra tutto

Abbott Laboratories Borsa (ABT) Ultime notizie

Jan 07, 2026

Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics (NASDAQ:EXAS) - Seeking Alpha

Jan 07, 2026

Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns - simplywall.st

Jan 07, 2026

17-year Abbott employee sues, alleges firing over approved FMLA use - HRD America

Jan 07, 2026

Abbott: Not Cheap, But Built To Compound In Uncertain Markets (NYSE:ABT) - Seeking Alpha

Jan 07, 2026

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy - The Globe and Mail

Jan 07, 2026

Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize

Jan 07, 2026

Jan 06, 2026

Abbott’s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT) - simplywall.st

Jan 06, 2026

Abbott Laboratories (NYSE:ABT) Given New $144.00 Price Target at Evercore ISI - MarketBeat

Jan 06, 2026

Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? - Yahoo Finance

Jan 06, 2026

Hematology Market Booming with Rapid Growth Through 2033 | - openPR.com

Jan 06, 2026